Evidence map›Paper›PMID 37777519›Full record

ArticleNPJ vaccines2023

Assessing immunogenicity barriers of the HIV-1 envelope trimer.

Liridona Maliqi, Nikolas Friedrich, Matthias Glögl, Stefan Schmutz, Daniel Schmidt, Peter Rusert, Merle Schanz, Maryam Zaheri, Chloé Pasin, Cyrille Niklaus and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Liridona Maliqi *Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Nikolas Friedrich *Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.ORCID http://orcid.org/0000-0003-0694-657X
Matthias GlöglInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Stefan SchmutzInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Daniel SchmidtInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Peter RusertInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Merle SchanzInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Maryam ZaheriInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Chloé PasinInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Cyrille NiklausInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Caio FoulkesInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Thomas ReinbergDepartment of Biochemistry, University of Zurich (UZH), Zurich, Switzerland.
Birgit DreierDepartment of Biochemistry, University of Zurich (UZH), Zurich, Switzerland.
Irene AbelaInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
David PeterhoffInstitute of Clinical Microbiology and Hygiene, University Hospital, Regensburg, Germany.
Alexandra HauserInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany.
Roger D KouyosInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
Huldrych F GünthardInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.ORCID http://orcid.org/0000-0002-1142-6723
Marit J van GilsDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-3422-8161
Rogier W SandersDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-2324-8573
Ralf WagnerInstitute of Clinical Microbiology and Hygiene, University Hospital, Regensburg, Germany.
Andreas PlückthunDepartment of Biochemistry, University of Zurich (UZH), Zurich, Switzerland.ORCID http://orcid.org/0000-0003-4191-5306
Alexandra TrkolaInstitute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland. trkola.alexandra@virology.uzh.ch.ORCID http://orcid.org/0000-0003-1013-876X

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 681032Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 314730_172790Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 33CS30_201369Swiss HIV Cohort Research Foundation 744
6 · The paper itself

Abstract

Understanding the balance between epitope shielding and accessibility on HIV-1 envelope (Env) trimers is essential to guide immunogen selection for broadly neutralizing antibody (bnAb) based vaccines. To investigate the antigenic space of Env immunogens, we created a strategy based on synthetic, high diversity, Designed Ankyrin Repeat Protein (DARPin) libraries. We show that DARPin Antigenicity Analysis (DANA), a purely in vitro screening tool, has the capability to extrapolate relevant information of antigenic properties of Env immunogens. DANA screens of stabilized, soluble Env trimers revealed that stronger trimer stabilization led to the selection of highly mutated DARPins with length variations and framework mutations mirroring observations made for bnAbs. By mimicking heterotypic prime-boost immunization regimens, DANA may be used to select immunogen combinations that favor the selection of trimer-reactive binders. This positions DANA as a versatile strategy for distilling fundamental antigenic features of immunogens, complementary to preclinical immunogenicity testing.

Identifiers

PMID37777519
PMCPMC10542815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.